Zevra Therapeutics will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open, March 1, 2023. The Company’s new corporate name, along with the corresponding ticker symbol, embody Zevra’s unwavering commitment to the rare disease community as it pursues its primary mission to deliver life-changing treatments to people with rare conditions, their families and caregivers who desperately need better options. Zevra expects several key milestones in 2023, including the planned resubmission of the New Drug Application for arimoclomol to the FDA as early as Q3 2023, an interim and final data readout for KP1077 in IH, and the potential achievement of one or more certain commercial sales milestones for our partnered asset, AZSTARYS, during FY 2023.
Published first on TheFly
